Moderna’s flu vaccine shows positive trial results, paving way for combo shot

Modern On Monday, the experimental MRNA -based flu vaccine has produced a more powerful immune response than an existing shot in a late stage attempt, and the product and the company cleans a path for separate combination flu and Covid Jab.

Moderna in May voluntarily withdrew an application Covid-19 and influenza’yı targeting the approval of the combination shot, the independent flu vaccine in the third stage attempt to re-send the event data, he said. This decision came after negotiations with the Food and Pharmaceutical Administration struggling with a great revision under the Secretary of Health and Human Services.

With new data, the company plans to re -send a combination vaccine and file application for the approved of independent flu shooting later this year in an interview.

Orum If the organizers approve the flu vaccine, the company may advance its combination shot, Hol Hoge said. Minister, Moderna expects approval for both shots for the investigations waiting for next year, he added.

Modernna stocks climbed more than 5% in marketing on Monday.

Hoge said that the combination is simplifying the vaccination of the combination, which is to “help the health system” by reducing the workloads of doctors and nurses, reducing costs and improving the purchase among patients.

So far it seems to be a pioneer in the race against the company Pfizer And Novavax To make a combination with the market. Although it does not have specific income projections for Moderna’s individual products, Hoge Covid, flu and respiratory sinitial virus is every multi -dollar market, he said.

“We hope our products will allow us to win our fair share of them,” he said.

The third stage attempt was followed by more than 40,000 adults aged 50 and over, and was appointed to get a random MRNA-1010 or a single moderna called a standard competitor vaccine. Moderna’s shot was 26.6% more effective than the other vaccine in the general working population.

MRNA-1010 JAB also showed strong activity for every major influenza strains in the shot, including A/H1N1, A/H3N2 and B/Victoria lineages. Moderna said that the benefits of the vaccine were consistent with different age groups, people with various risk factors and influenza.

In adults aged 65 years and older, firing is 27.4% more effective than standard flu vaccine.

Modernna CEO Stephane Bancel in a statement, the results of the event, “elderly adults are an important milestone in our efforts to reduce influenza burden,” he said. “The severity of this past flu season underlines the need for more effective vaccines.”

Quote moderna data Disease control and prevention centers, seasonal influenza hospitalization and outpatient visits to the virus in the 2024-2025 season has reached the highest level of 15 years. More than 600,000 Americans According to CDC, last year was taken to hospital because of influenza -related disease.

The security data of the MRNA-1010 vaccine were consistent with previous results of a third stage study in the shooting.

Moderna shares fell more than 30% for the year entering on Monday, largely fueled by a series of moves of the Trump administration to change the vaccine policy and weaken vaccines. Management in May canceled A contract given to Moderna for late stage development of bird flu vaccine.

When asked when the uncertain regulatory environment in the United States was asked, Hoge said that Moderna has closely interacted with the FDA to understand what the needs are and how to satisfy them.

“Regarding the flu, I think we have a very clear way,” he said.